Clinical Trial Update: Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a second-line therapy added to the FOLFOX regimen in colorectal cancer; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFOX regimen (folinic acid (leucovorin) + fluorouracil + oxaliplatin)

Snippet

Sponsor: AstraZeneca | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-10-24